case 2: maintenance in brca1/2wt, hr-proficient ovarian cancer
Published 4 years ago • 81 plays • Length 4:09Download video MP4
Download video MP3
Similar videos
-
4:17
case 2: olaparib in brca-mutated ovarian cancer
-
3:41
case 2: treating brca-mutated ovarian cancer
-
5:59
case 2: newly diagnosed ovarian cancer, gbrca-mutated
-
2:39
testing for brca and hrd in ovarian cancer
-
1:58
initial and maintenance treatments for ovarian cancer
-
0:43
molecular testing for brca1 in ovarian cancer
-
6:35
treatment options for patients with brca1/2
-
3:48
targeted therapies for patients with ovarian cancer who have brca-mutated tumors
-
3:48
treating ovarian cancer with a pfi less than 6 months
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
1:25
dr. zakashansky on solo2 with maintenance olaparib in relapsed brca1/2 ovarian cancer
-
6:52
case 3: benefit of parp inhibitor maintenance in ovarian cancer
-
4:31
maintenance therapy for advanced ovarian cancer
-
3:23
case 1: observation versus maintenance therapy in ovarian cancer
-
9:05
case 4: recurrent ovarian cancer, platinum-resistant, brca wt
-
0:54
potential of genetic testing beyond brca1/2 in ovarian cancer
-
3:48
case 3: maintenance therapy for recurrent ovarian cancer
-
28:57
2021 force | hereditary cancer | cancer risks, screening & prevention for brca1 or brca2 mutations
-
2:01:14
act genomics dinner symposium | moving from brca1/2 to hrd: beyond woman’s cancers